BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 26553313)

  • 1. Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
    Choe YM; Kim KW; Jhoo JH; Ryu SH; Seo EH; Sohn BK; Byun MS; Bak JH; Lee JM; Yun HJ; Han MI; Woo JI; Lee DY
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):731-9. PubMed ID: 26553313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.
    An H; Choi B; Park KW; Kim DH; Yang DW; Hong CH; Kim SY; Han SH
    J Alzheimers Dis; 2017; 55(2):727-735. PubMed ID: 27716660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
    Clayton AH; Croft HA; Horrigan JP; Wightman DS; Krishen A; Richard NE; Modell JG
    J Clin Psychiatry; 2006 May; 67(5):736-46. PubMed ID: 16841623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
    Waugh J; Goa KL
    CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Ehrhardt S; Porsteinsson AP; Munro CA; Rosenberg PB; Pollock BG; Devanand DP; Mintzer J; Rajji TK; Ismail Z; Schneider LS; Baksh SN; Drye LT; Avramopoulos D; Shade DM; Lyketsos CG;
    Alzheimers Dement; 2019 Nov; 15(11):1427-1436. PubMed ID: 31587995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
    Lepola UM; Loft H; Reines EH
    Int Clin Psychopharmacol; 2003 Jul; 18(4):211-7. PubMed ID: 12817155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram for treatment of night eating syndrome: a 12-week, randomized, placebo-controlled trial.
    Vander Wal JS; Gang CH; Griffing GT; Gadde KM
    J Clin Psychopharmacol; 2012 Jun; 32(3):341-5. PubMed ID: 22544016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study.
    Gauthier S; Aisen PS; Ferris SH; Saumier D; Duong A; Haine D; Garceau D; Suhy J; Oh J; Lau W; Sampalis J
    J Nutr Health Aging; 2009 Jun; 13(6):550-7. PubMed ID: 19536424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
    Burke WJ; Gergel I; Bose A
    J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of three rating scales as outcome measures for treatment trials of depression in Alzheimer disease: findings from DIADS.
    Mayer LS; Bay RC; Politis A; Steinberg M; Steele C; Baker AS; Rabins PV; Lyketsos CG
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):930-6. PubMed ID: 16955427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
    Dubois B; Chupin M; Hampel H; Lista S; Cavedo E; Croisile B; Louis Tisserand G; Touchon J; Bonafe A; Ousset PJ; Ait Ameur A; Rouaud O; Ricolfi F; Vighetto A; Pasquier F; Delmaire C; Ceccaldi M; Girard N; Dufouil C; Lehericy S; Tonelli I; Duveau F; Colliot O; Garnero L; Sarazin M; Dormont D; ;
    Alzheimers Dement; 2015 Sep; 11(9):1041-9. PubMed ID: 25596420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia.
    Kile S; Au W; Parise C; Rose K; Donnel T; Hankins A; Chan M; Ghassemi A
    J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):106-112. PubMed ID: 26420886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Cilostazol Administration in Alzheimer's Disease Patients with White Matter Lesions: A Positron-Emission Tomography Study.
    Lee JY; Lee H; Yoo HB; Choi JS; Jung HY; Yoon EJ; Kim H; Jung YH; Lee HY; Kim YK
    Neurotherapeutics; 2019 Apr; 16(2):394-403. PubMed ID: 30761509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial.
    Stahl SM; Gergel I; Li D
    J Clin Psychiatry; 2003 Nov; 64(11):1322-7. PubMed ID: 14658946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
    Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
    Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Escitalopram on All-Cause Mortality and Hospitalization in Patients With Heart Failure and Depression: The MOOD-HF Randomized Clinical Trial.
    Angermann CE; Gelbrich G; Störk S; Gunold H; Edelmann F; Wachter R; Schunkert H; Graf T; Kindermann I; Haass M; Blankenberg S; Pankuweit S; Prettin C; Gottwik M; Böhm M; Faller H; Deckert J; Ertl G;
    JAMA; 2016 Jun; 315(24):2683-93. PubMed ID: 27367876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
    Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.